Clinical Trial Update: Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 [Phase 2]

View source ↗

Summary

A Phase 2 open-label, multi-cohort study evaluating Becotatug Vedotin in combination with Tislelizumab and chemotherapy for esophageal squamous cell carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Becotatug Vedotin
• Chemotherapy (chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: ESCC, Tislelizumab | Phase 2 | Status: NOT_YET_RECRUITING